Skip to main content
. Author manuscript; available in PMC: 2024 Jul 30.
Published in final edited form as: Vaccine. 2024 May 3;42(16):3555–3563. doi: 10.1016/j.vaccine.2024.04.061

Table 4.

Serotype specific vaccine effectiveness against IPD for ≥ 1 doses of PCV13, by study period.

Exposure1 Serotype specific Cases Non-PCV13-type Controls Unadjusted Adjusted2







N (%) N (%) VE (95 % CI) VE (95 % CI)

Early PCV13 Implementation (May 1, 2010 - May 31, 2014)
Serotype 19A No doses of PCV13 81 (62.3) 93 (18.9) ref. ref.
≥1 dose PCV13 49 (37.7) 399 (81.1) 85.9 (78.7,90.8) 76.5 (58.9, 86.5)
Serotype 3 No doses of PCV13 17 (39.5) 93 (18.9) ref. ref.
≥1 dose PCV13 26 (60.5) 399 (81.1) 64.4 (32.2,81.5) 68.2 (19.6, 87.1)
Serotype 7F No doses of PCV13 30 (93.8) 93 (18.9) ref. ref.
≥1 dose PCV13 2 (6.2) 399 (81.1) 98.5 (93.4,99.6) 98.2 (89.9, 99.7)
Late PCV13 Implementation (June 1, 2014 - December 31, 2019)
Serotype 19A No doses of PCV13 8 (20.5) 32 (6.2) ref. ref.
≥1 dose PCV13 31 (79.5) 486 (93.8) 74.5 (40.4,89.3) 88.0 (58.2, 96.5)
Serotype 3 No doses of PCV13 5 (15.6) 32 (6.2) ref. ref.
≥1 dose PCV13 27 (84.4) 486 (93.8) 64.5 (2.4,87.3) 83.5 (11.3, 96.9)
Serotype 19F No doses of PCV 14 (34.1) 32 (6.2) ref. ref.
≥1 dose PCV13 27 (65.9) 486 (93.8) 87.3 (73.7,94.0) 94.1 (80.1, 98.2)
Full study period (May 1, 2010 - December 31, 2019)
Serotype 19A No doses of PCV13 89 (52.7) 125 (12.4) ref. ref.
≥1 dose PCV13 80 (47.3) 885 (87.6) 87.3 (82.0,91.1) 77.9 (65.6, 85.7)
Serotype 3 No doses of PCV13 22 (29.3) 125 (12.4) ref. ref.
≥1 dose PCV13 53 (70.7) 885 (87.6) 66.0 (42.6,80.1) 58.4 (19.0, 79.0)
Serotype 7F No doses of PCV13 30 (93.8) 125 (12.4) ref. ref.
≥1 dose PCV13 2 (6.2) 885 (87.6) 99.1 (96.0,99.8) 97.2 (86.6, 99.4)
Serotype 19F No doses of PCV 15 (33.3) 53 (5.7) ref. ref.
≥1 dose PCV13 30 (66.7) 885 (94.3) 88.0 (76.6,94.0) 92.7 (79.1, 97.3)

Abbreviations: VE = Vaccine Effectiveness; PCV = pneumococcal conjugate vaccine; PCV13- 13-valent pneumococcal conjugate vaccine; CI = confidence interval; ref. = reference level.

1

For the assessment of Serotype 19A, 3 and 7F VE, participants who received either 7-valent pneumococcal conjugate vaccine (PCV7) or no doses of any pneumococcal vaccination were included in the reference group (No doses of PCV13). For the assessment of Serotype 19F VE, participants were included in the reference group if they received no doses of any PCV products. Persons who received PCV7 only were excluded from this analysis.

2

Logistic regression model adjusted for age (categorical), race/ethnicity (combined variable), sex, state, calendar year, immunocompromising conditions, chronic conditions or asthma.